Suven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining stake a few months after FY2026-27, as per the terms of the definitive agreements, the company told stock exchanges.
As India sees the emergence of decentralised clinical trials driven by digital health technologies remote patient monitoring, Electronic Health Records andpatient data capture, it also sees robust rules like the US FDA’s Cancer Clinical Trial Eligibility Criteria as an advantage. Decentralised clinical trials allow patientsto participate in clinical trial in the comfort of patients’ homes, reducing the need for frequent visits to a clinical site.
Apollo HealthCo Limited (Apollo 24|7 or AHL), a subsidiary of Apollo Hospitals Enterprise Limited (AHEL) has today entered into a binding agreement to raise equity capital of Rs.2,475 crores from Advent International (Advent), one of the world's largest and most experienced global private equity investors.
Advent International and Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business
Private equity firm Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pe-advent-completes-acquisition-of-suven-pharma-appoints-new-board-and-management-team/articleshow/104050279.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Cabinet clears Advent's acquisition of Suven Pharma for Rs 9,589 crore
Reinventing Vitamin A for neonatal and pediatric unmet medical needsBronchopulmonary Dysplasia (BPD) is most frequent serious complication of preterm birth – US preterm births highest in 15...
DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough...
Advent International Appoints Biopharma Executive James Mullen as Operating Partner
Advent, CVC Are Among Suitors for €3 Billion Viatris OTC Assets